Dynavax Technologies Corporation (DVAX)
Dynavax Technologies Corporation (DVAX) is a biotechnology company specializing in the development and commercialization of vaccines for infectious diseases, oncology, and autoimmune conditions. The company is known for its COVID-19 vaccine, leveraging its expertise in immunology and vaccine technology to address various public health challenges.
Company News
Representative Haley Stevens announced plans to draft articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr., criticizing his healthcare policies and claiming he has caused 'health care chaos' and rising costs.
Dynavax Technologies exceeded Q2 2025 analyst expectations with $95.4 million in revenue and $0.14 EPS, driven by record sales of HEPLISAV-B hepatitis B vaccine and strong market share growth.
The global vaccine adjuvants market is projected to grow from USD 3.83 billion in 2024 to USD 5.43 billion by 2032, with a 4.47% CAGR, driven by increasing vaccine efficacy demands and global immunization programs.
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -40% and 2.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
